David Ke for almost 30 years has dedicated all of his efforts on the discovery and development of innovative drugs for treatment of serious musculoskeletal diseases. Before founding Angitia in 2018, David served as Vice President and the Head of Bone Therapeutic Area in UCB Pharma in the United Kingdom, and Scientific Executive Director and Head of Bone Research in Amgen Inc. in the United States, and also Research Fellow and Head of Bone Pharmacology in Pfizer Central Research and Development in the United States. As one of the major contributors, David led his teams to the successful discover and development of blockbuster innovative drugs for treatment of serious bone diseases that have been launched in United States, Europe, Japan, China, and other parts of the world. These innovative drugs included Prolia (osteoporosis), Xgeva (bone metastases) and Evenity (osteoporosis).
David’s research focuses have been on the disease pathophysiology of primary and secondary osteoporosis, delayed fracture healing, multiple myeloma-related bone diseases, bone tumors, muscle weakness, chronic kidney disease, osteoarthritis and rare musculoskeletal diseases. He has published 162 peer-reviewed scientific papers and review articles with more than 12,000 citations. David was the chairman of the International Conference of Osteoporosis and Bone Research co-organized by the Chinese Society of Osteoporosis and Bone Mineral Research and the International Bone and Mineral Society (IBMS). David is also one of the co-founders and former president of the International Chinese Musculoskeletal Research Society (ICMRS). He is currently on the Board of Director for the International Society of Bone Morphometry, a consultant for the Orthopedic Branch of the Chinese Society of Gerontology and Geriatrics, and an editorial board member of several international journals. He is also serving as a visiting professor at the University of Utah School of Medicine, the Chinese University of Hong Kong School of Medicine and Guangdong Medical University. As the founder of Angitia, David currently serves as Chairman of the Board and Chief Executive Officer of Angitia.